Maridebart Cafraglutide

DB19339InvestigationalProtein Based Therapies

Maridebart Cafraglutide is under investigation in clinical trial NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or...

Mechanism: Pharmacologically active on Glucagon-like peptide 1 receptor and Gastric inhibitory polypeptide receptor
Curator reviewed
Also known as: gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-33*01 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v64 CH2 C36, G1v54-30 CH2 C83, G8 · Immunoglobulin G1, anti-(glucose-dependent insulinotropic polypeptide receptor) [275-cysteine,295-cysteine,300-glycine,305-cysteine] (human γ1-chain), disulfide with human κ-chain, dimer, 275,275′-bis(thioether) with 7-37-glucagon-like peptide I [8-(
Code names: AMG-133

Resolves to

Compound

UNIIZ24U3U73HNCAS2760218-55-9

Targets

P43220GLP1RP48546GIPR

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

22Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Maridebart Cafraglutide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account